Literature DB >> 6098837

Adenosine and adenosine analogs inhibit phosphodiesterase activity in the heart.

W Meyer, M Nose, W Schmitz, H Scholz.   

Abstract

Adenosine and its analogs (-)-N6-phenylisopropyladenosine and 5'-N-ethylcarboxamideadenosine inhibit cAMP and cGMP phosphodiesterase activity in guinea-pig atrial and ventricular preparations at concentrations of 100 mumol l-1 and higher. These effects are probably unrelated to the inotropic effects of these substances. However, inhibition of cAMP breakdown may compensate for the adenosine-induced inhibition of adenylate cyclase and may thus at least partially explain why with this drug no changes in cAMP or cGMP content have previously been observed in intact cardiac tissue.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6098837     DOI： 10.1007/bf00512074

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


  19 in total

1.  EFFECTS OF CAFFEINE ON MAMMALIAN ATRIAL MUSCLE, AND ITS INTERACTION WITH ADENOSINE AND CALCIUM.

Authors:  T DEGUBAREFF; W SLEATOR
Journal:  J Pharmacol Exp Ther       Date:  1965-05       Impact factor: 4.030

2.  Reduction by adenosine of the isoproterenol-induced increase in cyclic adenosine 3',5'-monophosphate formation and glycogen phosphorylase activity in rat heart muscle.

Authors:  J G Dobson
Journal:  Circ Res       Date:  1978-11       Impact factor: 17.367

3.  Selective inhibition of separated forms of human platelet cyclic nucleotide phosphodiesterase by platelet aggregation inhibitors.

Authors:  T Asano; Y Ochiai; H Hidaka
Journal:  Mol Pharmacol       Date:  1977-05       Impact factor: 4.436

4.  Adenosine as inhibitor of myocardial effects of catecholamines.

Authors:  J Schrader; G Baumann; E Gerlach
Journal:  Pflugers Arch       Date:  1977-11-25       Impact factor: 3.657

5.  Effect of adenosine on cyclic AMP accumulation in ventricular myocardium.

Authors:  M Huang; G I Drummond
Journal:  Biochem Pharmacol       Date:  1976-12-15       Impact factor: 5.858

6.  Inhibition of cyclic 3',5'-nucleotide phosphodiesterase by adenine compounds.

Authors:  P F Gulyassy
Journal:  Life Sci II       Date:  1971-04-22

7.  Subclasses of external adenosine receptors.

Authors:  C Londos; D M Cooper; J Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

8.  Adenosine inhibition of catecholamine-induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations. Evidence against a cyclic AMP- and cyclic GMP-dependent effect.

Authors:  M Böhm; R Brückner; I Hackbarth; B Haubitz; R Linhart; W Meyer; B Schmidt; W Schmitz; H Scholz
Journal:  J Pharmacol Exp Ther       Date:  1984-08       Impact factor: 4.030

9.  Inhibition by adenosine of catecholamine-induced increase in rat atrial contractility.

Authors:  J B Rockoff; J G Dobson
Journal:  Am J Physiol       Date:  1980-09

10.  Evidence against adenylate cyclase-coupled adenosine receptors in the guinea pig heart.

Authors:  W Schütz; E Tuisl
Journal:  Eur J Pharmacol       Date:  1981-12-03       Impact factor: 4.432
View more
  3 in total

1.  Role of nucleoside transport and purine release in a rabbit model of myocardial stunning.

Authors:  A S Abd-Elfattah; R P Maddox; M E Jessen; I M Rebeyka; A S Wechsler
Journal:  Mol Cell Biochem       Date:  1998-03       Impact factor: 3.396

2.  Adenosine inhibits the positive inotropic effect of 3-isobutyl-1-methylxanthine in papillary muscles without effect on cyclic AMP or cyclic GMP.

Authors:  M Böhm; R Brückner; J Neumann; M Nose; W Schmitz; H Scholz
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

3.  Effects of saterinone and its enantiomers R(+)-saterinone and S(-)-saterinone on the phosphodiesterase isoenzymes from ventricular tissue of failing human hearts and porcine hearts.

Authors:  W Zimmermann; H Scholz; C Schumacher; H Wenzlaff; A Haverich
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-06       Impact factor: 3.000
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.